Product information and administration guide for Rybelsus (semaglutide) tablets in 3mg, 7mg, and 14mg strengths for type 2 diabetes treatment.
Rybelsus (semaglutide) is an oral medication used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is available in tablet strengths of 3 mg, 7 mg, and 14 mg.
The medication is a GLP-1 receptor agonist produced using recombinant DNA technology. It can be used as a monotherapy for patients who cannot tolerate metformin or in combination with other glucose-lowering medications. This manual is written in Chinese.
| Active Ingredient | semaglutide |
|---|---|
| Available Strengths | 3 mg, 7 mg, 14 mg |
| Sodium Content | 23 mg per tablet |
| Tablet Dimensions | 7.5 mm x 13.5 mm |
The starting dose is 3 mg daily for one month, then increased to a maintenance dose of 7 mg daily.
It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).